Market closed
Zenas BioPharma, Inc./$ZBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Ticker
$ZBIO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
130
Website
ZBIO Metrics
BasicAdvanced
$322M
-
-$11.89
-
-
Price and volume
Market cap
$322M
52-week high
$9.83
52-week low
$6.13
Financial strength
Current ratio
6.212
Quick ratio
6.122
Long term debt to equity
0.07
Total debt to equity
0.321
Management effectiveness
Return on assets (TTM)
-46.76%
Return on equity (TTM)
-93.22%
Valuation
Price to revenue (TTM)
20.353
Price to book
1.03
Price to tangible book (TTM)
1.03
Price to free cash flow (TTM)
-0.849
Growth
Revenue change (TTM)
-90.00%
Earnings per share change (TTM)
-50.94%
ZBIO News
AllArticlesVideos
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
Seeking Alpha·14 hours ago
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
GlobeNewsWire·22 hours ago
ROSEN, A RANKED AND LEADING FIRM, Encourages Zenas BioPharma, Inc. Investors to Inquire About Securities Class Action Investigation – ZBIO
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zenas BioPharma, Inc. stock?
Zenas BioPharma, Inc. (ZBIO) has a market cap of $322M as of April 08, 2025.
What is the P/E ratio for Zenas BioPharma, Inc. stock?
The price to earnings (P/E) ratio for Zenas BioPharma, Inc. (ZBIO) stock is 0 as of April 08, 2025.
Does Zenas BioPharma, Inc. stock pay dividends?
No, Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Zenas BioPharma, Inc. dividend payment date?
Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. (ZBIO) does not currently have a Beta indicator.